135 related articles for article (PubMed ID: 24755134)
1. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
Liu J; Chan-Tack KM; Jadhav P; Seo S; Robertson SM; Kraft J; Singer ME; Struble KA; Arya V
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):446-53. PubMed ID: 24755134
[TBL] [Abstract][Full Text] [Related]
2. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
[TBL] [Abstract][Full Text] [Related]
5. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
[TBL] [Abstract][Full Text] [Related]
8. Does tenofovir influence efavirenz pharmacokinetics?
Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A
Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
10. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Bolton Moore C; Capparelli EV; Samson P; Bwakura-Dangarembizi M; Jean-Philippe P; Worrell C; Heckman B; Purdue L; Spector SA; Benns A; Borkowsky W; Loftis A; Hawkins E; Wallis C; Chadwick EG;
AIDS; 2017 May; 31(8):1129-1136. PubMed ID: 28323755
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
14. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
15. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
16. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
17. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
[TBL] [Abstract][Full Text] [Related]
18. Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis.
Villar J; Sánchez P; González A; Sorli L; Montero MM; Guelar A; Solé E; López JL; Knobel H
HIV Clin Trials; 2011; 12(3):171-4. PubMed ID: 21684857
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
[TBL] [Abstract][Full Text] [Related]
20. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
Matteelli A; Regazzi M; Villani P; De Iaco G; Cusato M; Carvalho AC; Caligaris S; Tomasoni L; Manfrin M; Capone S; Carosi G
Curr HIV Res; 2007 May; 5(3):349-53. PubMed ID: 17504177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
